FDA guidelines for biosimilar biotech drugs are positive to Korean drug makers

The US Food and Drug Administration (FDA) has come up with guidelines for the sale of lower-cost versions of biotechnology drugs, issued on Thursday.

“These draft documents are designed to help the Korean drug industry develop biosimilar versions of currently approved biological products, which can enhance competition and may lead to better patient access and lower cost to consumers,” said C...